Another study in stage IIIB/IV NSCLC patients with EGFR mutations or ALK/ROS1 fusions who progressed after TKI therapy compared two regimens: one adding bevacizumab to platinum, pemetrexed, and atezolizumab, and the other using platinum, pemetrexed, and atezolizumab alone. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.